MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$31,630K
EPS
-$0.27
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
18,230
17,197
17,491
14,969
General and administrative
4,639
3,984
3,993
4,101
Total operating expenses
22,869
21,181
21,484
19,070
Loss from operations
-22,869
-21,181
-
-19,070
Other income, net
862
1,118
540
1,047
Change in fair value of warrant liabilities
9,623
18,962
-10,506
-564
Loss before income taxes
-
-
-10,438*
-
Provision for income taxes
-
-
9*
-
Net loss
-31,630
-39,025
-10,447
-17,459
Basic EPS
-0.27
-0.33
-0.109
-0.21
Diluted EPS
-0.27
-0.33
-0.109
-0.21
Basic Average Shares
113,631,565
112,424,211
95,906,085
77,156,068
Diluted Average Shares
113,631,565
112,424,211
95,906,085
77,156,068
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Net loss
-$31,630K
(-182.01%↓ Y/Y)
Other income, net
$862K
(-29.58%↓ Y/Y)
Loss from operations
-$22,869K
(7.54%↑ Y/Y)
Change in fair value of
warrant liabilities
$9,623K
(178.28%↑ Y/Y)
Total operating
expenses
$22,869K
(-7.54%↓ Y/Y)
Research and development
$18,230K
(-10.09%↓ Y/Y)
General and
administrative
$4,639K
(4.08%↑ Y/Y)
Buy us a coffee
Eledon Pharmaceuticals, Inc. (ELDN)
Eledon Pharmaceuticals, Inc. (ELDN)